Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry

Journal of Nuclear Medicine

Volumn 49, Issue 2, 2008, Pages 260-264

  Van De Wiele, Christophe ^a,b   Phonteyne, Philippe ^a,b   Pauwels, Patrick ^a   Goethals, Ingeborg ^a   Van Den Broecke, Rudi ^a   Cocquyt, Veronique ^a   Dierckx, Rudi Andre ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; RP 527 TC 99M; TAMOXIFEN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; BREAST LESION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 38949192477     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.047167     Document Type: Article

References (14)

1. Van de Wiele C, Dumont F, van Belle S, Slegers G, Peers SH, Dierckx RA. Is there a role for agonist gastrin releasing peptide receptor radioligands in tumour imaging? Nucl Med Commun. 2001;22:5-15.
2. Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm. 2007;4:652-658.
3. Van Eijck CH, Kwekkeboom DJ, Krenning EP. Somatostatin receptors in breast cancer. Q J Nucl Med. 1998;42:18-25.
4. 123I-Vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrintestinal tract. Nucl Med Biol. 1996;23:685-692.
5. Hofmann TJ, Simpson SD, Smith CJ, et al. Accumulation and retention of 99mTc RP527 by GRP receptor expressing tumors in SCID mice [abstract]. J Nucl Med. 1999;40(suppl):104P.
6. Van de Wiele C, Dumont F, Van den Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
7. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor expressing malignancies. J Nucl Med. 2001;42:1722-1727.
8. 123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck. Eur J Nucl Med Mol Imaging. 2007, October 10, 2007 [Epub ahead of print].
9. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55:280-287.
10. Gugger M, Reubi JC. Gastrin releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
11. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides. 2001;22:689-699.
12. Nagy A, Schally A. Targeting cytotixc conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des. 2005;11:1167-1180.
13. Panigone S, Nunn A. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging. 2006;50:310-321.
14. 18F-Labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.